BOLERO 3: Everolimus may overcome trastuzumab resistance in HER2-positive ... The Oncology Report CHICAGO – The mTOR inhibitor everolimus appears to be effective at overcoming trastuzumab resistance in patients with advanced HER2-positive breast cancer, based on findings from the BOLERO-3 trial. The 572 patients studied all had locally advanced ... |
